Evidence-based Recommendations for Atrial Fibrillation in Primary Care

Objectives

Evidence-based Recommendations for Atrial Fibrillation in Primary Care, published in February 2022, is an evidence-based clinical guideline for physicians, principally in primary-care clinics and consultation rooms. Its purpose is to improve accurate screening and diagnosis, provide effective non-pharmacological and pharmacological management, support follow-up, and prevent deterioration through appropriate referral.[1][2][3]The guideline covers identification and confirmation of atrial fibrillation, risk assessment, treatment, anticoagulation, follow-up, referral, associated conditions and special circumstances.[4][2]

• Assess stroke risk using the CHA₂DS₂-VASc score and support appropriate anticoagulation, including anticoagulation for men scoring 2 or more and women scoring 3 or more.[5][6][7]
• Prevent stroke, systemic embolism and bleeding complications by preferring non-vitamin K antagonist oral anticoagulants when initiating oral anticoagulation, while using vitamin K antagonists for moderate-to-severe mitral stenosis or mechanical heart valves.[8][7]
• Improve symptoms and quality of life through rhythm control for symptomatic atrial fibrillation and tachycardia-related heart failure, alongside rate control targeted initially at a resting heart rate of 110 beats per minute or below where appropriate.[9][6]
• Manage atrial fibrillation alongside heart failure, coronary artery disease, hypertension, chronic kidney disease, diabetes and thyroid disease, with additional guidance for very old people, peri-procedural anticoagulation and anticoagulant-associated bleeding.[2][10][11]
• Reduce treatment harms through bleeding-risk assessment, renal-function assessment, dose adjustment, medicine-interaction checks and referral where intensive rate or rhythm control is ineffective or poorly tolerated.[12][13][14][15]
• Support patient-centred care, education, self-management and participation in treatment decisions, including anticoagulant decisions intended to improve adherence.[16][17][18]

Implementation

The guideline uses a multidisciplinary, evidence-based adaptation and de novo development process led under the Korean Academy of Medical Sciences, with the Korean Heart Rhythm Society as lead society.[19]It was developed with nine professional societies and supported by an 11-member steering committee, a 19-member development committee, a guideline-development methodologist and a medical librarian.[20]Participating disciplines included arrhythmia, stroke, hypertension, thyroid disease, diabetes, nephrology, internal medicine, family medicine and general practice.[19][20]

• Identify and appraise evidence by screening 772 guideline records, selecting eight guidelines through predefined criteria and Appraisal of Guidelines for Research and Evaluation II assessment, and supplementing these sources with recent literature searches.[21][22][23]
• Develop recommendations through clinician-methodologist teams, standardised evidence extraction, recommendation matrices, evidence grading, benefit-harm assessment, feasibility and acceptability review, and the GRADE-ADOLOPMENT approach.[21][24][25]
• Classify evidence from systematic reviews and meta-analyses through randomised and observational studies, expert consensus and guideline-based evidence; apply recommendation grades that reflect evidence, benefits and harms, feasibility and primary-care applicability.[26][27][28]
• Consult users through a nine-point Delphi survey, external applicability and feasibility review, and feedback processes that informed recommendation summaries and the final guideline.[29][30][31]
• Apply recommendations in clinical consultations using defined patient groups, interventions, comparators and outcomes, with referral to specialists or higher-level institutions for selected patients with uncontrolled symptoms, structural heart disease, heart failure or poor medicine tolerance.[3][32][6]
• Monitor clinical care through repeated CHA₂DS₂-VASc and HAS-BLED assessment, adherence and adverse-event checks at visits, and haemoglobin, renal-function and liver-function testing according to patient risk.[13][33][15]
• Disseminate the guideline through recognition and publication by participating societies and the Korean Academy of Medical Sciences, digital publication, guideline registration, professional associations, academic conferences and postal distribution.[30]
• Investigate barriers to uptake, develop key indicators and monitor recommendation utilisation periodically; the source does not specify numerical implementation targets, reporting schedules or a formal accountability mechanism.[30][34]

Monitoring & Evaluation

The guideline combines evidence-development quality assurance with clinical follow-up measures, but it does not establish a comprehensive post-implementation performance-management or accountability framework. Development included appraisal of candidate guidelines using the Appraisal of Guidelines for Research and Evaluation II tool, structured risk-of-bias assessment, expert consensus, user surveys and external review of applicability and feasibility.[21][29][30][23][35]

• Assess draft recommendations through a nine-point Delphi survey covering acceptance, applicability and usefulness, and incorporate user feedback into final recommendations and summary materials.[29]Reported expert-consensus rates for clinical recommendations ranged from 79.8% to 97.9%, with mean scores from 7.5 to 8.6 on a nine-point scale.[36][37][38][39]
• Collect external user feedback on feasibility and applicability, undertake committee review, and periodically investigate barriers to dissemination and use.[30]Surveyed barriers included reluctance to change clinical practice, increased consultation time, staffing shortages, practical difficulties in applying recommendations, and concerns about reimbursement reductions.[40][41]
• Develop indicators and survey and monitor recommendation utilisation, although numerical targets, reporting schedules, responsible monitoring bodies and formal accountability arrangements are not specified.[30]
• Assess stroke risk using the CHA₂DS₂-VASc score and assess modifiable bleeding risk using the HAS-BLED score in people with atrial fibrillation receiving anticoagulation.[7][42]The CHA₂DS₂-VASc score is identified as an intervention indicator for predicting cerebral infarction or stroke risk.[5][43]
• Monitor anticoagulant adherence, embolic events, bleeding, adverse effects, concomitant medicines and medicine interactions at every visit.[13]Reassess stroke and bleeding risk at every visit.[33]
• Test haemoglobin and renal and liver function annually for all patients receiving anticoagulants, every four months for people aged 75 or over or frail older people, and more frequently where renal or hepatic function may change.[13][33]
• Assess renal function at least annually in anticoagulated patients with atrial fibrillation to identify kidney disease and support appropriate dose adjustment.[14][44]
• Evaluate rate-control management against quality of life, mortality, hospitalisation, worsening heart failure and achievement of heart-rate control.[6]Evaluate anticoagulation decisions against stroke, systemic embolism and bleeding outcomes.[8][12]
• Monitor anti-arrhythmic medicine safety with electrocardiograms before treatment and at specified post-initiation intervals, with treatment-interruption considerations including corrected QT interval above 500 milliseconds, QRS widening above 25%, and, for sotalol, QT increase above 60 milliseconds.[45][46]
• Assess bleeding risk initially and at every patient contact for people whose stroke risk warrants antithrombotic treatment, and arrange earlier, more frequent review for potentially high-risk patients, including those with a HAS-BLED score of 3 or more.[47][48][49]

Beyond these evidence-appraisal processes and clinical checks, the material does not specify routine data systems, surveillance arrangements, audit methods, implementation milestones, reporting requirements or institutional accountability mechanisms.[2][16][50][7]

Costing & Financing

The guideline provides very limited financing information. It does not set out a development or implementation budget, funding source, resource-mobilisation plan, allocation, funding gap, reimbursement amount or quantitative economic assumption.[51][30][24][7]

• Recognise that non-vitamin K antagonist oral anticoagulants have higher medicine costs than vitamin K antagonists.[8]
• Note that cost-benefit analyses from countries with generally high medical costs found non-vitamin K antagonist oral anticoagulants cost-effective compared with vitamin K antagonists.[8]
• Consider domestic reimbursement arrangements when drafting recommendations, although no reimbursement values, coverage rules or financial estimates are provided.[24]
• Recognise resource-related implementation barriers, including increased consultation time and staffing shortages, without quantified costs or a financing response.[40][41]
• Note that cited literature includes cost-effectiveness research on atrial-fibrillation screening, mobile-health devices, rate- and rhythm-control medicines, anticoagulants and incremental health-care costs, but the supplied material provides no associated monetary values or national funding decisions.[52][53][54][55]

No explicit costs are provided for clinical monitoring, laboratory testing, electrocardiography, referral, specialist care, catheter ablation, blood transfusion, patient education, digital dissemination or guideline-development activities.[13][56][51][30]